UY34346A - Proteínas de fusión para tratar trastornos metabólicos - Google Patents
Proteínas de fusión para tratar trastornos metabólicosInfo
- Publication number
- UY34346A UY34346A UY34346A UY34346A UY34346A UY 34346 A UY34346 A UY 34346A UY 34346 A UY34346 A UY 34346A UY 34346 A UY34346 A UY 34346A UY 34346 A UY34346 A UY 34346A
- Authority
- UY
- Uruguay
- Prior art keywords
- fusion proteins
- metabolic disorders
- treat metabolic
- treat
- disorders
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
- 208000030159 metabolic disease Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
La invención se refiere a la identificación de proteínas de fusión que comprenden variantes polipep tídicas y proteicos del factor de crecimiento de fibroblastos 21 (FGF21) que tienen propiedades far macéuticas mejoradas. También se describen métodos para el tratamiento de trastornos asociados con el FGF21, incluyendo trastornos metabólicos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161539280P | 2011-09-26 | 2011-09-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY34346A true UY34346A (es) | 2013-04-30 |
Family
ID=46970456
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY34346A UY34346A (es) | 2011-09-26 | 2012-09-25 | Proteínas de fusión para tratar trastornos metabólicos |
| UY0001039119A UY39119A (es) | 2011-09-26 | 2021-03-08 | Proteínas de fusión para tratar trastornos metabólicos |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001039119A UY39119A (es) | 2011-09-26 | 2021-03-08 | Proteínas de fusión para tratar trastornos metabólicos |
Country Status (42)
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8394921B2 (en) | 2006-07-25 | 2013-03-12 | Lipoxen Technologies Limited | N-terminal derivatisation of proteins with polysaccharides |
| KR20140012199A (ko) | 2007-03-30 | 2014-01-29 | 암브룩스, 인코포레이티드 | 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도 |
| US8822663B2 (en) | 2010-08-06 | 2014-09-02 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| CN104531671A (zh) | 2010-10-01 | 2015-04-22 | 现代治疗公司 | 设计核酸及其使用方法 |
| CA2831613A1 (en) | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| MX349869B (es) | 2011-07-01 | 2017-08-17 | Ngm Biopharmaceuticals Inc | Composiciones, usos y metodos para tratamiento de trastornos y enfermedades metabolicas. |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| US9458214B2 (en) | 2011-09-26 | 2016-10-04 | Novartis Ag | Dual function fibroblast growth factor 21 proteins |
| UY34346A (es) * | 2011-09-26 | 2013-04-30 | Novartis Ag | Proteínas de fusión para tratar trastornos metabólicos |
| BR112014007852B1 (pt) | 2011-10-03 | 2021-11-03 | Moderna Therapeutics, Inc | Polinucleotídeo isolado modificado e composição farmacêutica |
| AU2012352180A1 (en) | 2011-12-16 | 2014-07-31 | Moderna Therapeutics, Inc. | Modified nucleoside, nucleotide, and nucleic acid compositions |
| WO2013151672A2 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of oncology-related proteins and peptides |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| RS63237B1 (sr) | 2012-11-26 | 2022-06-30 | Modernatx Inc | Terminalno modifikovana rnk |
| ES2828505T3 (es) | 2012-11-28 | 2021-05-26 | Ngm Biopharmaceuticals Inc | Composiciones y métodos para el tratamiento de trastornos y enfermedades metabólicos |
| US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
| US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| SG11201504815QA (en) | 2012-12-27 | 2015-07-30 | Ngm Biopharmaceuticals Inc | Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| JP2016538829A (ja) | 2013-10-03 | 2016-12-15 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 低密度リポタンパク質受容体をコードするポリヌクレオチド |
| EP3057605A1 (en) | 2013-10-18 | 2016-08-24 | Novartis AG | Methods of treating diabetes and related disorders |
| WO2015065897A1 (en) | 2013-10-28 | 2015-05-07 | Ngm Biopharmaceuticals, Inc. | Cancer models and associated methods |
| SG11201606018UA (en) | 2014-01-24 | 2016-08-30 | Ngm Biopharmaceuticals Inc | Binding proteins and methods of use thereof |
| US20170065678A1 (en) * | 2014-03-11 | 2017-03-09 | Novartis Ag | Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling |
| WO2015183890A2 (en) | 2014-05-28 | 2015-12-03 | Ngm Biopharmaceuticals, Inc. | Methods and compositions for the treatment of metabolic disorders and diseases |
| US10456449B2 (en) | 2014-06-16 | 2019-10-29 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| SG11201702757YA (en) * | 2014-10-23 | 2017-05-30 | Ngm Biopharmaceuticals Inc | Pharmaceutical compositions comprising peptide variants and methods of use thereof |
| MX2017004947A (es) | 2014-10-24 | 2017-06-29 | Bristol Myers Squibb Co | Polipeptidos del factor de crecimiento de fibroblastos 2 (fgf-21) modificados y usos de los mismos. |
| US10434144B2 (en) | 2014-11-07 | 2019-10-08 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
| KR20160088656A (ko) | 2015-01-16 | 2016-07-26 | 주식회사유한양행 | 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물 |
| WO2017019957A2 (en) | 2015-07-29 | 2017-02-02 | Ngm Biopharmaceuticals, Inc. | Binding proteins and methods of use thereof |
| RU2752530C2 (ru) | 2015-08-03 | 2021-07-29 | Новартис Аг | Способы лечения расстройств, связанных с fgf21 |
| EP3888672A1 (en) | 2015-11-09 | 2021-10-06 | NGM Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders |
| TW201731867A (zh) * | 2015-12-02 | 2017-09-16 | 賽諾菲公司 | Ｆｇｆ２１變異體 |
| CN117535350A (zh) * | 2016-05-20 | 2024-02-09 | 哈佛学院董事及会员团体 | 年龄相关疾病和病症的基因治疗方法 |
| EP3463427A4 (en) * | 2016-05-25 | 2020-03-11 | Board of Regents, The University of Texas System | Methods and compositions for the treatment of secretory disorders |
| US11123438B2 (en) | 2016-08-19 | 2021-09-21 | Ampsource Biopharma Shanghai Inc. | Linker peptide for constructing fusion protein |
| CN106279437B (zh) | 2016-08-19 | 2017-10-31 | 安源医药科技（上海）有限公司 | 高糖基化人凝血因子viii融合蛋白及其制备方法与用途 |
| CN107759694B (zh) * | 2016-08-19 | 2023-01-13 | 安源医药科技（上海）有限公司 | 双特异性抗体及其制备方法与用途 |
| US11370841B2 (en) | 2016-08-26 | 2022-06-28 | Ngm Biopharmaceuticals, Inc. | Methods of treating fibroblast growth factor 19-mediated cancers and tumors |
| CA3047862A1 (en) | 2016-12-22 | 2018-06-28 | Sanofi | Fgf21 compound / glp-1r agonist combinations with optimized activity ratio |
| CN108570109B (zh) * | 2017-03-14 | 2022-04-26 | 广东东阳光药业有限公司 | 包含免疫球蛋白Fc部分的双靶点融合蛋白 |
| CN107050429B (zh) * | 2017-04-01 | 2020-12-15 | 杭州生物医药创新研究中心 | 人成纤维生长因子21在制备用于治疗脑卒中药物中的应用 |
| JP2020518287A (ja) * | 2017-05-05 | 2020-06-25 | トレフォイル セラピューティクス，インク． | 組み換え修飾された繊維芽細胞成長因子及びその治療用途 |
| CN109836504B (zh) * | 2017-11-24 | 2022-08-02 | 浙江道尔生物科技有限公司 | 一种治疗代谢疾病的多结构域活性蛋白 |
| CN111518770B (zh) | 2017-12-19 | 2023-01-06 | 北京吉源生物科技有限公司 | 一种表达glp1和fgf21的干细胞及其用途 |
| FI3727423T3 (fi) * | 2017-12-22 | 2024-07-04 | Novartis Ag | Aineenvaihduntahäiriöiden hoito FGF21-varianteilla |
| US11679143B2 (en) | 2018-02-08 | 2023-06-20 | Sunshine Lake Pharma Co., Ltd. | FGF21 variant, fusion protein and application thereof |
| PE20210632A1 (es) | 2018-07-03 | 2021-03-23 | Bristol Myers Squibb Co | Formulaciones de fgf-21 |
| CN111195234B (zh) * | 2018-11-16 | 2022-08-26 | 鲁南制药集团股份有限公司 | 一种重组FGF21-Fc融合蛋白冻干粉制剂 |
| EP3736574A1 (en) * | 2019-05-07 | 2020-11-11 | Atlas Antibodies AB | A formulation comprising an isotope labeled fusion polypeptide |
| CN114853908B (zh) | 2019-05-16 | 2024-06-07 | 浙江道尔生物科技有限公司 | 一种治疗代谢疾病的融合蛋白 |
| CN112386575B (zh) * | 2019-08-19 | 2023-03-21 | 鲁南制药集团股份有限公司 | 一种代谢调节融合蛋白的冻干制剂 |
| WO2021050789A1 (en) | 2019-09-10 | 2021-03-18 | Obsidian Therapeutics, Inc. | Ca2-il15 fusion proteins for tunable regulation |
| AU2020408067B2 (en) | 2019-12-20 | 2024-03-28 | Novartis Ag | Combination treatment of liver diseases using integrin inhibitors |
| JP6924291B2 (ja) | 2020-01-21 | 2021-08-25 | シャープ株式会社 | 端末装置、方法、および、集積回路 |
| US11981718B2 (en) | 2020-05-27 | 2024-05-14 | Ampsource Biopharma Shanghai Inc. | Dual-function protein for lipid and blood glucose regulation |
| WO2022101853A1 (en) | 2020-11-16 | 2022-05-19 | Novartis Ag | Method of determining liver fibrosis |
| CN113265007B (zh) * | 2021-06-10 | 2022-02-15 | 江南大学 | 一种治疗代谢疾病的融合蛋白及其制备方法和应用 |
| CN115286705B (zh) * | 2021-12-30 | 2024-05-10 | 长江大学 | 一种黄鳝成纤维细胞因子21重组蛋白及其制备方法和应用 |
| WO2023245543A1 (en) * | 2022-06-23 | 2023-12-28 | Ampsource Biopharma Shanghai Inc. | Uses of fgf21 fusion proteins |
| WO2024123812A1 (en) | 2022-12-05 | 2024-06-13 | Shattuck Labs, Inc. | Fusion proteins for the treatment of cardiometabolic diseases |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| DE3474511D1 (en) | 1983-11-01 | 1988-11-17 | Terumo Corp | Pharmaceutical composition containing urokinase |
| EP0315456B1 (en) | 1987-11-05 | 1994-06-01 | Hybritech Incorporated | Polysaccharide-modified immunoglobulins having reduced immunogenic potential or improved pharmacokinetics |
| US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
| US5470582A (en) | 1992-02-07 | 1995-11-28 | Syntex (U.S.A.) Inc. | Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles |
| US5234784A (en) | 1992-04-01 | 1993-08-10 | Eastman Kodak Company | Method of making a projection viewable transparency comprising an electrostatographic toner image |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| CA2249195A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| US7459540B1 (en) * | 1999-09-07 | 2008-12-02 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
| US6716626B1 (en) | 1999-11-18 | 2004-04-06 | Chiron Corporation | Human FGF-21 nucleic acids |
| DE60043197D1 (es) | 1999-11-18 | 2009-12-03 | Univ Kyoto | |
| EP2248828A1 (en) | 1999-12-23 | 2010-11-10 | ZymoGenetics, Inc. | Method for treating inflammation |
| WO2003011213A2 (en) | 2001-07-30 | 2003-02-13 | Eli Lilly And Company | Method for treating diabetes and obesity |
| EP1673395A1 (en) | 2003-10-15 | 2006-06-28 | PDL BioPharma, Inc. | Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig |
| CN1890371A (zh) * | 2003-12-10 | 2007-01-03 | 伊莱利利公司 | 成纤维细胞生长因子的21突变蛋白 |
| EP1751184B1 (en) * | 2004-05-13 | 2009-09-30 | Eli Lilly And Company | Fgf-21 fusion proteins |
| AU2005283025B2 (en) * | 2004-09-02 | 2011-06-30 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
| EP1846019A2 (en) | 2005-01-21 | 2007-10-24 | Eli Lilly And Company | Method for treating cardiovascular disease |
| JOP20190083A1 (ar) * | 2008-06-04 | 2017-06-16 | Amgen Inc | بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها |
| AU2009308163B2 (en) | 2008-10-24 | 2013-01-10 | Novartis Ag | Biosynthetically generated pyrroline-carboxy-lysine and site specific protein modifications via chemical derivatization of pyrroline-carboxy-lysine and pyrrolysine residues |
| PL3248610T3 (pl) * | 2009-05-05 | 2024-04-02 | Amgen Inc. | Mutanty fgf21 i ich zastosowania |
| WO2010129600A2 (en) | 2009-05-05 | 2010-11-11 | Amgen Inc. | Fgf21 mutants and uses thereof |
| WO2010148142A1 (en) * | 2009-06-17 | 2010-12-23 | Amgen Inc. | Chimeric fgf19 polypeptides and uses thereof |
| MX2012007318A (es) | 2009-12-22 | 2012-07-20 | Novartis Ag | Proteina de fusion de la region constante del anticuerpo-cd47 tetravalente para usarse en terapia. |
| DE102010038140B4 (de) * | 2010-10-13 | 2020-06-18 | Hettich-Heinze Gmbh & Co. Kg | Beschlag für eine Schiebetür |
| US9023791B2 (en) | 2010-11-19 | 2015-05-05 | Novartis Ag | Fibroblast growth factor 21 mutations |
| US9458214B2 (en) * | 2011-09-26 | 2016-10-04 | Novartis Ag | Dual function fibroblast growth factor 21 proteins |
| UY34346A (es) | 2011-09-26 | 2013-04-30 | Novartis Ag | Proteínas de fusión para tratar trastornos metabólicos |
| US20170065678A1 (en) | 2014-03-11 | 2017-03-09 | Novartis Ag | Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling |
-
2012
- 2012-09-25 UY UY34346A patent/UY34346A/es active IP Right Grant
- 2012-09-25 US US13/626,194 patent/US9006400B2/en active Active
- 2012-09-25 TW TW101135183A patent/TWI593708B/zh active
- 2012-09-25 JO JOP/2012/0279A patent/JO3476B1/ar active
- 2012-09-26 MX MX2014003677A patent/MX350273B/es active IP Right Grant
- 2012-09-26 EP EP17201957.2A patent/EP3321276B1/en active Active
- 2012-09-26 PE PE2014000418A patent/PE20141551A1/es active IP Right Grant
- 2012-09-26 RS RS20211120A patent/RS62341B1/sr unknown
- 2012-09-26 HU HUE12768999A patent/HUE039857T2/hu unknown
- 2012-09-26 PT PT12768999T patent/PT2760475T/pt unknown
- 2012-09-26 AU AU2012316052A patent/AU2012316052A1/en not_active Abandoned
- 2012-09-26 PE PE2018001106A patent/PE20181159A1/es unknown
- 2012-09-26 AP AP2014007543A patent/AP2014007543A0/xx unknown
- 2012-09-26 AR ARP120103553 patent/AR088044A1/es active IP Right Grant
- 2012-09-26 IN IN2043DEN2014 patent/IN2014DN02043A/en unknown
- 2012-09-26 LT LTEP12768999.0T patent/LT2760475T/lt unknown
- 2012-09-26 WO PCT/US2012/057384 patent/WO2013049247A1/en active Application Filing
- 2012-09-26 ES ES17201957T patent/ES2895080T3/es active Active
- 2012-09-26 HR HRP20211575TT patent/HRP20211575T1/hr unknown
- 2012-09-26 EA EA201490695A patent/EA039633B1/ru unknown
- 2012-09-26 HU HUE17201957A patent/HUE055584T2/hu unknown
- 2012-09-26 ES ES12768999.0T patent/ES2689762T3/es active Active
- 2012-09-26 MY MYPI2014700650A patent/MY166059A/en unknown
- 2012-09-26 SG SG11201400538QA patent/SG11201400538QA/en unknown
- 2012-09-26 KR KR1020147010946A patent/KR102085605B1/ko active IP Right Grant
- 2012-09-26 CU CUP2015000171A patent/CU24314B1/es unknown
- 2012-09-26 DK DK17201957.2T patent/DK3321276T3/da active
- 2012-09-26 PL PL17201957T patent/PL3321276T3/pl unknown
- 2012-09-26 CN CN201710255835.5A patent/CN107266579B/zh active Active
- 2012-09-26 UA UAA201402419A patent/UA113856C2/uk unknown
- 2012-09-26 EP EP12768999.0A patent/EP2760475B1/en active Active
- 2012-09-26 SG SG10201602339XA patent/SG10201602339XA/en unknown
- 2012-09-26 PL PL12768999T patent/PL2760475T3/pl unknown
- 2012-09-26 LT LTEP17201957.2T patent/LT3321276T/lt unknown
- 2012-09-26 BR BR112014007069-5A patent/BR112014007069B1/pt active IP Right Grant
- 2012-09-26 PT PT17201957T patent/PT3321276T/pt unknown
- 2012-09-26 SI SI201231952T patent/SI3321276T1/sl unknown
- 2012-09-26 SI SI201231391T patent/SI2760475T1/sl unknown
- 2012-09-26 DK DK12768999.0T patent/DK2760475T3/en active
- 2012-09-26 SM SM20210595T patent/SMT202100595T1/it unknown
- 2012-09-26 CA CA2849464A patent/CA2849464C/en active Active
- 2012-09-26 CN CN201280057789.3A patent/CN103945871B/zh active Active
- 2012-09-26 RS RS20181146A patent/RS57868B1/sr unknown
- 2012-09-26 JP JP2014532117A patent/JP6186361B2/ja active Active
-
2014
- 2014-03-07 ZA ZA2014/01700A patent/ZA201401700B/en unknown
- 2014-03-12 TN TNP2014000109A patent/TN2014000109A1/en unknown
- 2014-03-13 IL IL231533A patent/IL231533B/en active IP Right Grant
- 2014-03-13 MA MA36824A patent/MA35437B1/fr unknown
- 2014-03-25 CL CL2014000736A patent/CL2014000736A1/es unknown
- 2014-03-26 CR CR20140140A patent/CR20140140A/es unknown
- 2014-03-26 CU CUP2014000034A patent/CU24206B1/es active IP Right Grant
- 2014-03-26 CO CO14064516A patent/CO6920257A2/es unknown
- 2014-03-26 GT GT201400055A patent/GT201400055A/es unknown
- 2014-09-30 HK HK18110595.8A patent/HK1251238A1/zh unknown
-
2015
- 2015-02-24 US US14/630,206 patent/US9266935B2/en active Active
-
2016
- 2016-01-04 US US14/987,338 patent/US10076554B2/en active Active
- 2016-09-02 CL CL2016002215A patent/CL2016002215A1/es unknown
-
2017
- 2017-07-28 JP JP2017146984A patent/JP6567613B2/ja active Active
-
2018
- 2018-08-30 US US16/117,960 patent/US11129874B2/en active Active
- 2018-09-28 HR HRP20181558TT patent/HRP20181558T1/hr unknown
- 2018-10-03 CY CY181101017T patent/CY1120928T1/el unknown
-
2019
- 2019-07-31 JP JP2019141242A patent/JP2020007314A/ja not_active Withdrawn
-
2021
- 2021-03-08 UY UY0001039119A patent/UY39119A/es not_active Application Discontinuation
- 2021-08-24 US US17/410,307 patent/US11944664B2/en active Active
- 2021-10-06 CY CY20211100868T patent/CY1124697T1/el unknown
- 2021-10-25 AR ARP210102949A patent/AR123908A2/es unknown
-
2022
- 2022-01-11 JP JP2022002030A patent/JP7339372B2/ja active Active
-
2024
- 2024-02-07 US US18/435,440 patent/US20240261372A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY34346A (es) | Proteínas de fusión para tratar trastornos metabólicos | |
| UY34347A (es) | Proteínas de función dual para tratar trastornos metabólicos | |
| BR112013023241A2 (pt) | melhorias para entidades biológicas imobilizadas | |
| CO7020912A2 (es) | Inhibidores de bromodominios | |
| EP2760463A4 (en) | REGULATION OF SODIUM CHANNELS BY PLUNC PROTEINS | |
| BR112013028251A2 (pt) | polipeptídeo | |
| BR112013028187A2 (pt) | processo para produzir olefinas | |
| UY33909A (es) | Metodo para producir fibra de lignina | |
| UY34483A (es) | Polipeptido | |
| BR112014026326A2 (pt) | composição para tratamento de distúrbios metabólicos | |
| UY34158A (es) | Composicion herbicida | |
| DK2783256T3 (da) | Terapeutiske briller | |
| BR112013028178A2 (pt) | unidade para transportar segmentos de filtro | |
| BR112014005877A2 (pt) | cápsula para preparar uma bebida | |
| CO6880064A2 (es) | Métodos terapéuticos | |
| EP2739764A4 (en) | ION SOURCE | |
| BR112013031686A2 (pt) | fusão de moléculas bioativas | |
| BR112013030090A2 (pt) | métodos para tratar biomassa | |
| UY33996A (es) | Preparacion sólida | |
| TH148777B (th) | ฟิวชั่นโปรตีนสำหรับบำบัดความผิดปกติเกี่ยวกับเมทาบอลิซึม | |
| TN2011000420A1 (fr) | طريقة علمية لمقاومة التصحر وتخصيب الصحراء | |
| TN2011000287A1 (fr) | حذاء مولد للطاقة | |
| BR112013032338A2 (pt) | método para melhorar o rendimento de produção para proteína l1 do papilomavírus humano | |
| FI20115295A0 (fi) | Valoterapiamuoto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 110 | Patent granted |
Effective date: 20220322 |